1
|
Tsubata Y, Ohtsu H, Hotta T, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T. MA10.04 A New Predictive Score for Venous Thromboembolism Associated with Advanced Lung Cancer: A Multicenter, Prospective Study (Rising-VTE/NEJ037). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
2
|
Ohta T, Fujiwara M, Hotta T, Ide I, Ishizaki K, Kohri H, Yanai Y, Yosoi M. Monitoring the build-up of hydrogen polarization for polarized hydrogen-deuteride (HD) targets with nuclear magnetic resonance (NMR) at 17 T. Rev Sci Instrum 2020; 91:095104. [PMID: 33003818 DOI: 10.1063/5.0005696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 08/20/2020] [Indexed: 06/11/2023]
Abstract
We report on the frozen-spin polarized hydrogen-deuteride (HD) targets for photoproduction experiments at SPring-8/LEPS. Pure HD gas with a small amount of ortho-H2 (∼0.1%) and a very small amount of para-D2 (∼0.001%) was liquefied and solidified by liquid helium. The temperature of the produced solid HD was reduced to about 30 mK with a dilution refrigerator. A magnetic field (17 T) was applied to the HD to grow the polarization with the static method. After the aging of the HD at low temperatures in the presence of a high-magnetic field strength for three months, the polarization froze. Almost all ortho-H2 molecules were converted to para-H2 molecules. Most remaining para-D2 molecules were converted to ortho-D2 molecules. The para-H2 and ortho-D2 molecules exhibited weak spin interactions with the HD. If the concentrations of the ortho-H2 and para-D2 were reduced appropriately at the beginning of the aging process, the aging time can be shortened. We have developed a new nuclear magnetic resonance (NMR) system to measure the relaxation times (T1) of the 1H and 2H nuclei with two frequency sweeps at the respective frequencies of 726 MHz and 111 MHz and succeeded in the monitoring of the polarization build-up at decreasing temperatures from 600 mK to 30 mK at 17 T. Automatic NMR measurements with the frequency sweeps enabled us to omit the use of a manual tuning circuit and to remove magnetic field sweeps with eddy current heat. This technique enables us to optimize the concentration of the ortho-H2 and to efficiently polarize the HD target within a shortened aging time.
Collapse
Affiliation(s)
- T Ohta
- Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - I Ide
- Nagoya University, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - K Ishizaki
- Nagoya University, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
3
|
Tomida N, Muramatsu N, Niiyama M, Ahn JK, Chang WC, Chen JY, Chu ML, Daté S, Gogami T, Goto H, Hamano H, Hashimoto T, He QH, Hicks K, Hiraiwa T, Honda Y, Hotta T, Ikuno H, Inoue Y, Ishikawa T, Jaegle I, Jo JM, Kasamatsu Y, Katsuragawa H, Kido S, Kon Y, Maruyama T, Masumoto S, Matsumura Y, Miyabe M, Mizutani K, Nagahiro H, Nakamura T, Nakano T, Nam T, Ngan TNT, Nozawa Y, Ohashi Y, Ohnishi H, Ohta T, Ozawa K, Rangacharyulu C, Ryu SY, Sada Y, Sasagawa M, Shibukawa T, Shimizu H, Shirai R, Shiraishi K, Strokovsky EA, Sugaya Y, Sumihama M, Suzuki S, Tanaka S, Tokiyasu A, Tsuchikawa Y, Ueda T, Yamazaki H, Yamazaki R, Yanai Y, Yorita T, Yoshida C, Yosoi M. Search for η^{'} Bound Nuclei in the ^{12}C(γ,p) Reaction with Simultaneous Detection of Decay Products. Phys Rev Lett 2020; 124:202501. [PMID: 32501086 DOI: 10.1103/physrevlett.124.202501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 02/11/2020] [Accepted: 04/30/2020] [Indexed: 06/11/2023]
Abstract
We measured missing mass spectrum of the ^{12}C(γ,p) reaction for the first time in coincidence with potential decay products from η^{'} bound nuclei. We tagged an (η+p) pair associated with the η^{'}N→ηN process in a nucleus. After applying kinematical selections to reduce backgrounds, no signal events were observed in the bound-state region. An upper limit of the signal cross section in the opening angle cosθ_{lab}^{ηp}<-0.9 was obtained to be 2.2 nb/sr at the 90% confidence level. It is compared with theoretical cross sections, whose normalization ambiguity is suppressed by measuring a quasifree η^{'} production rate. Our results indicate a small branching fraction of the η^{'}N→ηN process and/or a shallow η^{'}-nucleus potential.
Collapse
Affiliation(s)
- N Tomida
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Niiyama
- Department of Physics, Kyoto Sangyo University, Kyoto 603-8555, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J Y Chen
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - M L Chu
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S Daté
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Japan Synchrotron Radiation Research Institute (SPring-8), Sayo, Hyogo 679-5198, Japan
| | - T Gogami
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Goto
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Hamano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hashimoto
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Q H He
- Department of Nuclear Science & Engineering, College of Material Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - T Hiraiwa
- RIKEN SPring-8 Center, Sayo, Hyogo 679-5148, Japan
| | - Y Honda
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Ikuno
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Inoue
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - I Jaegle
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J M Jo
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - Y Kasamatsu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Katsuragawa
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Kido
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Institute for Radiation Sciences, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Maruyama
- College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-8510, Japan
| | - S Masumoto
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - Y Matsumura
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Mizutani
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Nagahiro
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Nara Women's University, Nara 630-8506, Japan
| | - T Nakamura
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Nam
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T N T Ngan
- Nuclear Physics Department, University of Science, Vietnam National University, Ho Chi Minh City 72711, Vietnam
| | - Y Nozawa
- Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Y Ohashi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Ohnishi
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Ohta
- Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - K Ozawa
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon SK S7N 5E2, Canada
| | - S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Sada
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Sasagawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Shibukawa
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - R Shirai
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Shiraishi
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Laboratory of High Energy Physics, Joint Institute for Nuclear Research, Dubna, Moscow Region 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - S Suzuki
- Japan Synchrotron Radiation Research Institute (SPring-8), Sayo, Hyogo 679-5198, Japan
| | - S Tanaka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - A Tokiyasu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Tsuchikawa
- J-PARC Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ueda
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - H Yamazaki
- Radiation Science Center, High Energy Accelerator Research Organization (KEK), Tokai, Ibaraki 319-1195, Japan
| | - R Yamazaki
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Yorita
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - C Yoshida
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
4
|
Ko R, Oizumi S, Mizugaki H, Fujita Y, Harada T, Takashina T, Igawa S, Watanabe K, Hotta T, Minemura H, Saeki S, Yagishita S, Hamada A. P1.14-36 Phase II Trial of Afatinib in Elderly Patients Aged Over 75 Years with EGFR Mutation Positive Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Tsubata Y, Hamai K, Furuya N, Hata T, Saito R, Masuda T, Hotta T, Hamaguchi M, Kuyama S, Honda R, Nakano K, Nakanishi M, Funaishi K, Yamasaki M, Ishikawa N, Fujitaka K, Kubota T, Kobayashi K, Isobe T. MA13.02 Incidence of Venous Thromboembolism at the Time of Lung Cancer Diagnosis: A Multicenter, Prospective Observational Trial (Rising-VTE/NEJ037). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
6
|
Ogura M, Ohmachi K, Suzuki R, Atsuta Y, Ito T, Ohyashiki K, Yano S, Hidaka M, Ando K, Fukuhara N, Morishita Y, Suzuki T, Tsukasaki K, Kobayashi N, Tsukamoto K, Ozawa Y, Yamamoto K, Hotta T, Kinoshita T. A PHASE II STUDY OF THP (PIRARUBICIN)-COP THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED PTCL: THP-3 STUDY OF JAPAN HEMATOPOIETIC MALIGNANCY CLINICAL STUDY GROUP. Hematol Oncol 2019. [DOI: 10.1002/hon.147_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Ogura
- Hematology and Oncology/Hematology and Oncology; Kasugai Municipal Hospital/Nagoya Daini Red Cross Hospital; Kasugai/Nagoya Japan
| | - K. Ohmachi
- Hematology and Oncology; Tokai University School of Medicine; Isehara Japan
| | - R. Suzuki
- Oncology and Hematology; Shimane University Hospital; Izumo Japan
| | - Y. Atsuta
- Data Center; Japanese Data Center for Hematopoietic Cell Transplantation; Nagoya Japan
| | - T. Ito
- Hematology and Oncology; Anjyo Kosei Hospital; Anjo Japan
| | - K. Ohyashiki
- Hematology; Tokyo Medical University; Tokyo Japan
| | - S. Yano
- Clinical Oncology and Hematology; Jikei University School of Medicine; Tokyo Japan
| | - M. Hidaka
- Hematology; National Hospital Organization; Kumamoto Japan
| | - K. Ando
- Hematology and Oncology; Tokai University School of Medicine; Isehara Japan
| | - N. Fukuhara
- Hematology and Rheumatology; Tohoku University Hospital; Sendai Japan
| | - Y. Morishita
- Hematology and Oncology; Konan Kosei Hospital; Konan Japan
| | - T. Suzuki
- Hematology; Shiga Medical Center for Adults; Moriyama Japan
| | - K. Tsukasaki
- Hematology; Nagasaki University Hospital; Nagasaki Japan
| | - N. Kobayashi
- Hematology; Sapporo Hokuyu Hospital; Sapporo Japan
| | - K. Tsukamoto
- Medicine and Clinical Science; Gunma University Graduate School of Medicine; Maebashi Japan
| | - Y. Ozawa
- Hematology; Japanese Red Cross Nagoya First Hospital; Nagoya Japan
| | - K. Yamamoto
- Hematology and Cell Therapy; Aichi Cancer Center; Nagoya Japan
| | - T. Hotta
- President; Nagoya Medical Center; Nagoya Japan
| | - T. Kinoshita
- Hematology and Cell Therapy; Aichi Cancer Center; Nagoya Japan
| |
Collapse
|
7
|
Kawashima H, Ariizumi T, Yamagishi T, Ogose A, Ikoma M, Hotta T, Endo N. Symptom Burden and End-of-Life Palliative Treatments during the Last Two Weeks of Life in Patients with Advanced Musculoskeletal Sarcoma. J Palliat Med 2019; 22:908-914. [PMID: 30762454 DOI: 10.1089/jpm.2018.0415] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: Musculoskeletal sarcomas (MSSs) are rare cancers and often aggressive tumors that originate from mesenchymal tissue. Patients with advanced MSS often report difficulties with symptom burden, which can reduce their health-related quality-of-life. Objective: The aim of this study was to describe the patterns of the physical symptoms of MSS patients in the palliative setting and to detail the palliative treatment used in the last two weeks of life. Design: Retrospective study using the electronic patient records from a single institution. Setting/Subjects: A retrospective study was carried out in a sample of 46 consecutive MSS patients with locally advanced/metastatic disease, who were hospitalized and died in our department. The median age of these patients was 56 years at death. Measurements: Symptom burden and medical intervention during the last two weeks of life were collected. Results: The most frequent physical symptoms were pain and dyspnea in 93% and 78% of patients, respectively, while only 17% of patients suffered from nausea. A total of 98% of patients required opioids, and most patients were treated with morphine through either subcutaneous or intravenous continuous injection. Nonsteroidal anti-inflammatory drugs and acetaminophen were administered to 79% of patients. Corticosteroids were administered for the relief of dyspnea to 83% of patients. Of the patients, 46% received palliative chemotherapy within the last two weeks of life, and the oral treatment was continued until a median of 5.6 days before death. In addition, 39% of patients received a sedative treatment during the last two weeks of life for uncontrolled refractory symptoms. Conclusions: The symptom burden experienced by advanced MSS patients is profound at the end of life for all palliative approaches. Therefore, palliative medicine is an important and even crucial component of the continuum of care, allowing for aggressive symptom management with a variety of medical interventions, including palliative sedation.
Collapse
Affiliation(s)
- Hiroyuki Kawashima
- 1Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.,2Palliative Care Team, Niigata University Medical and Dental Hospital, Niigata, Japan
| | - Takashi Ariizumi
- 1Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Tetsuro Yamagishi
- 1Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Akira Ogose
- 3Department of Orthopedic Surgery, Uonuma Kikan Hospital, Niigata, Japan
| | - Miho Ikoma
- 2Palliative Care Team, Niigata University Medical and Dental Hospital, Niigata, Japan.,4Division of Palliative Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Tetsuo Hotta
- 1Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Naoto Endo
- 1Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| |
Collapse
|
8
|
Nakahara Y, Oizumi S, Mizugaki H, Fujita Y, Harada T, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Yagishita S, Hamada A. Phase II trial of afatinib in elderly patients over 75 years of age with EGFR mutation positive NSCLC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
9
|
Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T, Sasaki T, Yamagishi T, Umezu H, Endo N. Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci 2018; 109:3043-3054. [PMID: 30133055 PMCID: PMC6172059 DOI: 10.1111/cas.13769] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 08/07/2018] [Accepted: 08/08/2018] [Indexed: 12/12/2022] Open
Abstract
The association between the immune status within the tumor microenvironment and prognosis in synovial sarcoma is not well understood. We aimed to investigate the tumor immune microenvironment and analyze its prognostic impact for patients with synovial sarcoma. A total of 36 primary patients who were treated in our institution were retrospectively evaluated. Infiltration of lymphocytes (CD4+, CD8+, and FOXP3+), CD163+ macrophages, and expression of human leukocyte antigen (HLA) class I and programmed death ligand 1 (PD-L1) were evaluated by immunohistochemistry. Moreover, we investigated PD-L1 and programmed death ligand 2 (PD-L2) mRNA expression in 19 of the 36 cases, using real-time PCR. The Kaplan-Meier method was used to estimate overall survival and progression-free survival. Infiltration of lymphocytes and macrophages varied among the patients. Furthermore, the expression of HLA class I was negative or downregulated in 11 specimens. No PD-L1 expression was observed using immunohistochemistry. Moreover, although PD-L1 mRNA expression was observed in 18 of 19 specimens, the expression level was low. A higher infiltration of CD8+ or FOXP3+ lymphocytes in patients was associated with a favorable overall survival. In addition, a higher infiltration of CD163+ macrophages indicated a significantly worse overall and progression-free survival. Infiltration of CD4+ lymphocytes, HLA class I, PD-L1, and PD-L2 expression were not associated with patient prognosis. This represents the first report investigating the tumor immune microenvironment as a prognostic factor in synovial sarcoma, indicating that CD163+ macrophages are associated with tumor progression. Our results underscore the clinical significance of the tumor immune microenvironment in synovial sarcoma.
Collapse
Affiliation(s)
- Naoki Oike
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Akira Ogose
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.,Department of Orthopedic Surgery, Uonuma Kikan Hospital, Niigata, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Hiroshi Hatano
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Taro Sasaki
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Tetsuro Yamagishi
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Hajime Umezu
- Department of Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| |
Collapse
|
10
|
Kohri H, Shiu SH, Chang WC, Yanai Y, Ahn DS, Ahn JK, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Gohn W, Hicks K, Hosaka A, Hotta T, Hwang SH, Imai K, Ishikawa T, Joo K, Kato Y, Kon Y, Lee HS, Maeda Y, Mibe T, Miyabe M, Morino Y, Muramatsu N, Nakano T, Nakatsugawa Y, Nam SI, Niiyama M, Noumi H, Ohashi Y, Ohta T, Oka M, Parker JD, Rangacharyulu C, Ryu SY, Sawada T, Shimizu H, Strokovsky EA, Sugaya Y, Sumihama M, Tsunemi T, Uchida M, Ungaro M, Wang SY, Yosoi M. Differential Cross Section and Photon-Beam Asymmetry for the γ[over →]p → π^{-}Δ^{++}(1232) Reaction at Forward π^{-} Angles for E_{γ}=1.5-2.95 GeV. Phys Rev Lett 2018; 120:202004. [PMID: 29864366 DOI: 10.1103/physrevlett.120.202004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 03/11/2018] [Indexed: 06/08/2023]
Abstract
Differential cross sections and photon-beam asymmetries for the γ[over →]p→π^{-}Δ^{++}(1232) reaction have been measured for 0.7<cosθ_{π}^{c.m.}<1 and E_{γ}=1.5-2.95 GeV at SPring-8/LEPS. The first-ever high statistics cross-section data are obtained in this kinematical region, and the asymmetry data for 1.5<E_{γ}(GeV)<2.8 are obtained for the first time. This reaction has a unique feature for studying the production mechanisms of a pure uu[over ¯] quark pair in the final state from the proton. Although there is no distinct peak structure in the cross sections, a non-negligible excess over the theoretical predictions is observed at E_{γ}=1.5-1.8 GeV. The asymmetries are found to be negative in most of the present kinematical regions, suggesting the dominance of π exchange in the t channel. The negative asymmetries at forward meson production angles are different from the asymmetries previously measured for the photoproduction reactions producing a dd[over ¯] or an ss[over ¯] quark pair in the final state. Advanced theoretical models introducing nucleon resonances and additional unnatural-parity exchanges are needed to reproduce the present data.
Collapse
Affiliation(s)
- H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S H Shiu
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Department of Physics, National Central University, Taoyuan City 32001, Taiwan
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - D S Ahn
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - J Y Chen
- Light Source Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - S Daté
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Fujimura
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- National Institutes for Quantum and Radiological Science and Technology, Tokai, Ibaraki 319-1195, Japan
| | - S Fukui
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - W Gohn
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - A Hosaka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S H Hwang
- Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Joo
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - Y Kato
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H S Lee
- Rare Isotope Science Project, Institute for Basic Science, Daejeon 34047, Korea
| | - Y Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, Fukui 910-8526, Japan
| | - T Mibe
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Morino
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Nakatsugawa
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S I Nam
- Department of Physics, Pukyong National University (PKNU), Busan 608-737, Republic of Korea
| | - M Niiyama
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Noumi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Ohashi
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Ohta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Oka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - J D Parker
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E2, Canada
| | - S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Sawada
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Physics Department, University of Michigan, Michigan 48109-1040, USA
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Joint Institute for Nuclear Research, Dubna, Moscow Region 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - T Tsunemi
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Uchida
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Ungaro
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - S Y Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
11
|
Sasaki T, Kawashima H, Ariizumi T, Yamagishi T, Oike N, Umezu H, Inagawa S, Hotta T, Endo N, Ogose A. Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report. Mol Clin Oncol 2018; 8:30-33. [PMID: 29387393 PMCID: PMC5769267 DOI: 10.3892/mco.2017.1489] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 10/26/2017] [Indexed: 11/06/2022] Open
Abstract
Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.
Collapse
Affiliation(s)
- Taro Sasaki
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Niigata 951-8510, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Tetsuro Yamagishi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Naoki Oike
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Hajime Umezu
- Division of Pathology, Niigata University Medical and Dental Hospital, Niigata, Niigata 951-8510, Japan
| | - Shyoichi Inagawa
- Division of Radiology, Niigata University Medical and Dental Hospital, Niigata, Niigata 951-8510, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata 951-8510, Japan
| | - Akira Ogose
- Department of Orthopedic Surgery, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Niigata, Niigata 951-8510, Japan
| |
Collapse
|
12
|
Kawashima H, Ogose A, Hotta T, Ariizumi T, Yamagishi T, Endo N. Extensor reconstruction of the knee using the fibular transposition technique after proximal tibial resection. Knee 2017; 24:657-662. [PMID: 27916576 DOI: 10.1016/j.knee.2016.11.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 09/24/2016] [Accepted: 11/07/2016] [Indexed: 02/02/2023]
Abstract
BACKGROUND Reconstruction of the extensor mechanism after resection of the proximal tibia is challenging, and several surgical procedures are available. The purpose of this study was to determine the outcome of the fibular transposition technique for reconstruction of the extensor mechanism of the knee after proximal tibial resection. METHODS We retrospectively reviewed five consecutive patients who underwent resection of the proximal tibia with prosthetic reconstruction and reconstruction of the extensor using fibular transposition between 1997 and 2011. There were two female and three male patients with a mean age of 50years (range, 27 to 76years). A follow-up evaluation included both passive and active range of motion, extensor lag, the MSTS score and complications. RESULTS Patients were followed up for 93months (range, 44 to 160months). The mean extensor lag and active flexion were four degrees (range, 0 to 10°) and 103° (range, 85 to 110°), respectively. The mean MSTS score was 80% (range, 73 to 90%). All patients were able to ambulate without crutches at the latest follow-up. CONCLUSIONS The utilization of the fibular transposition technique is a simple, reliable, and successful procedure for extensor reconstruction after proximal tibial resection.
Collapse
Affiliation(s)
- Hiroyuki Kawashima
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
| | - Akira Ogose
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Tetsuro Yamagishi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| |
Collapse
|
13
|
Oike N, Kawashima H, Ogose A, Hotta T, Hirano T, Ariizumi T, Yamagishi T, Umezu H, Inagawa S, Endo N. A malignant solitary fibrous tumour arising from the first lumbar vertebra and mimicking an osteosarcoma: a case report. World J Surg Oncol 2017; 15:100. [PMID: 28494796 PMCID: PMC5426015 DOI: 10.1186/s12957-017-1161-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2016] [Accepted: 04/23/2017] [Indexed: 12/23/2022] Open
Abstract
Background A solitary fibrous tumour (SFT) is an unusual neoplasm typically found in soft tissues. Although SFTs can arise in the bones, they very rarely arise in the vertebral arch. Here, we describe a case of a SFT that arose in the vertebral arch of the first lumbar (L1) spinal vertebrae and mimicked osteosarcoma. Case presentation A 49-year-old woman presented with a 2-month history of lower back pain and a lumbar region mass. Magnetic resonance imaging demonstrated a heterogeneously enhanced mass in the L1 vertebral arch. The patient received neoadjuvant chemotherapy, followed by a surgical procedure comprising an anterior spinal fusion and en bloc resection. Histologically, our initial diagnosis was osteosarcoma. The postoperative course was uneventful, and the patient received adjuvant chemotherapy. However, the tumour metastasised to the lung 5 years after the first surgery, and a second surgery was performed for lung tumour resection. The histology of the metastatic lung tumour appeared similar to that of the malignant SFT, and the specimen from the first surgery was re-examined. Immunohistochemically, the tumour was positive for STAT6. Reverse transcription-polymerase chain reaction revealed a NAB2-STAT6 fusion gene, thus confirming our final diagnosis of malignant SFT. The patient died of disease progression 8 years after the first surgery; however, there was no evidence of local recurrence. Conclusions Malignant SFT in the vertebral arch is extremely rare and very difficult to distinguish histologically an osteoid from lace-like collagen. STAT6 immunostaining is useful for distinguishing malignant SFTs from other neoplasms. Although it is difficult to completely resect a SFT arising from the spine, we demonstrated the feasibility of an en bloc resection of spinal tumours arising from posterior elements, without local recurrence.
Collapse
Affiliation(s)
- Naoki Oike
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan.
| | - Akira Ogose
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Toru Hirano
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Tetsuro Yamagishi
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| | - Hajime Umezu
- Division of Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Shoichi Inagawa
- Division of Radiology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan
| |
Collapse
|
14
|
Hotta T, Takifuji K, Yokoyama S, Matsuda K, Ieda J, Watanabe T, Tamura K, Mitani Y, Iwamoto H, Takei Y, Mizumoto Y, Tsumura A, Deguchi M, Yamaue H. Horizontal rectal transection using an endolinear stapler for laparoscopic low anterior resection. Tech Coloproctol 2017; 21:311-313. [DOI: 10.1007/s10151-017-1617-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 04/03/2017] [Indexed: 10/19/2022]
|
15
|
Ogose A, Kawashima H, Hotta T, Ariizumi T, Yamagishi T, Oike N, Sasaki T, Hatano H, Umezu H, Endo N. Frequent expression of human leukocyte antigen class I and the status of intratumoral immune cells in alveolar soft part sarcoma. Oncol Lett 2017; 13:2169-2176. [PMID: 28454377 PMCID: PMC5403429 DOI: 10.3892/ol.2017.5696] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Accepted: 12/16/2016] [Indexed: 12/03/2022] Open
Abstract
The prognosis of alveolar soft part sarcoma is poor, despite the slow growth of the tumor. A number of cases with spontaneous regression of this rare tumor have been reported. Although the mechanisms underlying spontaneous regression remain uncertain, local immune reaction may be a possible contributing factor. Immunohistochemical expression of human leukocyte antigen (HLA) class I, cluster of differentiation (CD) 3, CD4, CD8, CD20, CD45, CD56, CD68, CD138 and CD163 were assessed in a series of 10 alveolar soft part sarcomas, and the expression profiles were associated with patients' clinicopathological parameters. Expression of HLA class I was observed in almost all the tumor cells of all cases. CD8(+) cells were identified in all tumors with varying densities. Moderate infiltration of CD8(+) cells was detected in three patients; one of these patients survived with long-term tumor remission. Infiltration of CD10(+), CD20(+), CD56(+) or CD138(+) cells was not revealed in all tumors. Moderate-diffuse infiltration of CD163(+) cells was observed in all tumors. To the best of our knowledge, the present study represents the first report of intratumoral immune cells in alveolar soft part sarcoma. Frequent expression of HLA class I in tumor cells was observed. CD8(+) cells were identified at various densities and CD163(+) cells were observed in alveolar soft part sarcoma. Moderate infiltration of CD8(+) cells in patients with a good prognosis may indicate the antitumor effects of immune cells in alveolar soft part sarcoma.
Collapse
Affiliation(s)
- Akira Ogose
- Department of Orthopedic Surgery, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minami-Uonuma, Niigata 949-7320, Japan.,Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Tetsuro Yamagishi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Naoki Oike
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Taro Sasaki
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata 951-8566, Japan
| | - Hiroshi Hatano
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata 951-8566, Japan
| | - Hajime Umezu
- Division of Pathology, Niigata University Medical and Dental Hospital, Niigata 951-8510, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| |
Collapse
|
16
|
Ryu SY, Ahn JK, Nakano T, Ahn DS, Ajimura S, Akimune H, Asano Y, Chang WC, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Hasegawa S, Hicks K, Horie K, Hotta T, Hwang SH, Imai K, Ishikawa T, Iwata T, Kato Y, Kawai H, Kino K, Kohri H, Kon Y, Kumagai N, Lin PJ, Maeda Y, Makino S, Matsuda T, Matsuoka N, Mibe T, Miyabe M, Miyachi M, Morino Y, Muramatsu N, Murayama R, Nakatsugawa Y, Nam SI, Niiyama M, Nomachi M, Ohashi Y, Ohkuma H, Ohta T, Ooba T, Oshuev DS, Parker JD, Rangacharyulu C, Sakaguchi A, Sawada T, Shagin PM, Shiino Y, Shimizu H, Strokovsky EA, Sugaya Y, Sumihama M, Tokiyasu AO, Toi Y, Toyokawa H, Tsunemi T, Uchida M, Ungaro M, Wakai A, Wang CW, Wang SC, Yonehara K, Yorita T, Yoshimura M, Yosoi M, Zegers RGT. Interference Effect between ϕ and Λ(1520) Production Channels in the γp→K^{+}K^{-}p Reaction near Threshold. Phys Rev Lett 2016; 116:232001. [PMID: 27341225 DOI: 10.1103/physrevlett.116.232001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Indexed: 06/06/2023]
Abstract
The ϕ-Λ(1520) interference effect in the γp→K^{+}K^{-}p reaction has been measured for the first time in the energy range from 1.673 to 2.173 GeV. The relative phases between ϕ and Λ(1520) production amplitudes were obtained in the kinematic region where the two resonances overlap. The measurement results support strong constructive interference when K^{+}K^{-} pairs are observed at forward angles but destructive interference for proton emission at forward angles. Furthermore, the observed interference effect does not account for the sqrt[s]=2.1 GeV bump structure in forward differential cross sections for ϕ photoproduction. This fact suggests possible exotic structures such as a hidden-strangeness pentaquark state, a new Pomeron exchange, or rescattering processes via other hyperon states.
Collapse
Affiliation(s)
- S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - D S Ahn
- RIKEN, The Institute of Physical and Chemical Research, Wako, Saitama 351-0198, Japan
| | - S Ajimura
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Akimune
- Department of Physics, Konan University, Kobe, Hyogo 658-8501, Japan
| | - Y Asano
- XFEL Project Head Office, RIKEN, Sayo, Hyogo 679-5143, Japan
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J Y Chen
- Light Source Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - S Daté
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Fujimura
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Fukui
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Hasegawa
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - K Horie
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S H Hwang
- Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Iwata
- Department of Physics, Yamagata University, Yamagata 990-8560, Japan
| | - Y Kato
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - H Kawai
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - K Kino
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - N Kumagai
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - P J Lin
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - Y Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, Fukui 910-8526, Japan
| | - S Makino
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - T Matsuda
- Department of Applied Physics, Miyazaki University, Miyazaki 889-2192, Japan
| | - N Matsuoka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Mibe
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Miyachi
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - Y Morino
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - R Murayama
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Nakatsugawa
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S I Nam
- Department of Physics, Pukyong National University, Busan 48513, Republic of Korea
| | - M Niiyama
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Nomachi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Ohashi
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ohkuma
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Ohta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Ooba
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - D S Oshuev
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J D Parker
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E2, Canada
| | - A Sakaguchi
- Department of Physics, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - T Sawada
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - P M Shagin
- School of Physics and Astronomy, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | - Y Shiino
- Department of Physics, Chiba University, Chiba 263-8522, Japan
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Joint Institute for Nuclear Research, Dubna, Moscow Region, 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - A O Tokiyasu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Toi
- Department of Applied Physics, Miyazaki University, Miyazaki 889-2192, Japan
| | - H Toyokawa
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Tsunemi
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Uchida
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Ungaro
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - A Wakai
- Akita Research Institute of Brain and Blood Vessels, Akita 010-0874, Japan
| | - C W Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S C Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - K Yonehara
- Department of Physics, Konan University, Kobe, Hyogo 658-8501, Japan
| | - T Yorita
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Yoshimura
- Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - R G T Zegers
- National Superconducting Cyclotron Laboratory, Michigan State University, East Lansing, Michigan 48824, USA
| |
Collapse
|
17
|
Yamagishi T, Kawashima H, Ogose A, Ariizumi T, Sasaki T, Hatano H, Hotta T, Endo N. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors. PLoS One 2016; 11:e0154680. [PMID: 27163152 PMCID: PMC4862691 DOI: 10.1371/journal.pone.0154680] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 04/18/2016] [Indexed: 11/19/2022] Open
Abstract
The receptor-activator of nuclear kappaB ligand (RANKL) signaling pathway plays an important role in the regulation of bone growth and mediates the formation and activation of osteoclasts. Osteoclasts are involved in significant bone resorption and destruction. Denosumab is a fully human monoclonal antibody against RANKL that specifically inhibits osteoclast differentiation and bone resorption. It has been approved for use for multiple myeloma and bone metastases, as well as for giant cell tumor of bone. However, there is no previous report quantitatively, comparing RANKL expression in histologically varied bone tumors. Therefore, we analyzed the mRNA level of various bone tumors and investigated the possibility of these tumors as a new therapeutic target for denosumab. We examined RANKL mRNA expression in 135 clinical specimens of primary and metastatic bone tumors using real-time PCR. The relative quantification of mRNA expression levels was performed via normalization with RPMI8226, a human multiple myeloma cell line that is recognized to express RANKL. Of 135 cases, 64 were also evaluated for RANKL expression by using immunohistochemistry. Among all of the tumors investigated, RANKL expression and the RANKL/osteoprotegerin ratio were highest in giant cell tumor of bone. High RANKL mRNA expression was observed in cases of aneurysmal bone cyst, fibrous dysplasia, osteosarcoma, chondrosarcoma, and enchondroma, as compared to cases of multiple myeloma and bone lesions from metastatic carcinoma. RANKL-positive stromal cells were detected in six cases: five cases of GCTB and one case of fibrous dysplasia. The current study findings indicate that some primary bone tumors present new therapeutic targets for denosumab, particularly those tumors expressing RANKL and those involving bone resorption by osteoclasts.
Collapse
Affiliation(s)
- Tetsuro Yamagishi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- * E-mail:
| | - Akira Ogose
- Department of Orthopedic Surgery, Uonuma Kikan Hospital, Minamiuonuma, Niigata, Japan
| | - Takashi Ariizumi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Taro Sasaki
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Hiroshi Hatano
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| |
Collapse
|
18
|
Yamagishi T, Kawashima H, Ogose A, Sasaki T, Hotta T, Inagawa S, Umezu H, Endo N. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: A case report. Oncol Lett 2015; 11:243-246. [PMID: 26870196 DOI: 10.3892/ol.2015.3858] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Accepted: 09/09/2015] [Indexed: 12/18/2022] Open
Abstract
A giant-cell tumor of the bone (GCTB) is a benign but locally aggressive bone tumor. Recently, the receptor activator of nuclear factor κB (RANK) ligand inhibitor, denosumab, has demonstrated activity against giant-cell tumors. The current study reports a case of a sacral GCTB with lung metastasis. A 19-year-old male patient presented with right buttock pain and right lower leg pain, and a sacral GCTB was diagnosed based on the histological analysis of a biopsy specimen. The patient was successfully treated with neoadjuvant denosumab therapy, which allowed curettage. In addition, the pulmonary nodule reduced in size following denosumab administration, and surgical resection was performed. Since the operation, the patient has been managed with the continued use of denosumab with no sign of recurrence. Microscopic findings from the surgical specimen following denosumab treatment revealed that the giant cells had disappeared and woven bone had formed. The specimen from the pulmonary nodule exhibited similar findings to the surgical specimen. It was reported that denosumab treatment was able to reduce the number of giant cells and RANK-positive stromal cells, and cause the formation of new bone in the primary lesion. The present study reports the first case to demonstrate the efficiency of denosumab in treating pulmonary metastasis of GCTB.
Collapse
Affiliation(s)
- Tetsuro Yamagishi
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | - Akira Ogose
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | - Taro Sasaki
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | - Shoichi Inagawa
- Division of Radiology, Niigata University Medical and Dental Hospital, Niigata 951-8510, Japan
| | - Hajime Umezu
- Division of Pathology, Niigata University Medical and Dental Hospital, Niigata 951-8510, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| |
Collapse
|
19
|
Hidehiko S, Nishiguchi S, Fukutani N, Adachi D, Tashiro Y, Hotta T, Morino S, Nozaki Y, Hirata H, Yamaguchi M, Aoyama T. O-015: Health literacy is associated with frailty stage in community-dwelling elderly people. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30029-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N. Effect of temozolomide on the viability of musculoskeletal sarcoma cells. Oncol Lett 2015; 10:2511-2518. [PMID: 26622881 DOI: 10.3892/ol.2015.3506] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Accepted: 06/16/2015] [Indexed: 01/22/2023] Open
Abstract
Musculoskeletal sarcomas (MSS) are a heterogeneous group of malignancies with relatively high mortality rates. The prognosis for patients with MSS is poor, with few drugs inducing measurable activity. Alkylating agents, namely ifosfamide and dacarbazine, which act nonspecifically on proliferating cells, are the typical therapy prescribed for advanced MSS. A novel alkylating agent, temozolomide (TMZ), has several advantages over existing alkylating agents. TMZ induces the formation of O6-methylguanine in DNA, thereby inducing mismatches during DNA replication and the subsequent activation of apoptotic pathways. However, due to conflicting data in the literature, the mechanism of TMZ action has remained elusive. Therefore, the present study aimed to evaluate apoptosis in MSS cells treated with TMZ, and to evaluate the correlation between TMZ action and survival pathways, including the phosphoinositide 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK)1/2 mitogen activated protein kinase (MAPK) pathways. Cell proliferation was evaluated by performing an XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) assay. Apoptotic morphological changes, for example chromatin condensation, were evaluated by fluorescence confocal microscopy. The expression of the apoptosis-associated proteins caspase-3, poly adenosine diphosphate ribose polymerase (PARP), Akt and ERK1/2, was determined by western blotting. The results of the present study indicated that, in certain MSS cells, the IC50 value was lower than that in TMZ-sensitive U-87 MG cells. Furthermore, TMZ treatment was associated with apoptotic morphological changes and the expression levels of pro-apoptotic cleaved caspase-3 and PARP were also increased in TMZ-treated MSS cells. In addition, the results indicated that PI3K/Akt and ERK1/2 MAPK were constitutively phosphorylated in MSS cells, and phosphorylation of PI3K/Akt was suppressed in certain cells, and maintained in other cells, by TMZ. These observations emphasized the plasticity of MSS cells, and suggested that this plasticity may contribute to the variance in cell sensitivity to TMZ and TMZ-resistance in MSS.
Collapse
Affiliation(s)
- Yuta Kusabe
- School of Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| | - Hiroyuki Kawashima
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| | - Akira Ogose
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| | - Taro Sasaki
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| | - Takashi Ariizumi
- Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata 951-8566, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851-8510, Japan
| |
Collapse
|
21
|
Kawashima H, Ogose A, Hotta T, Imai C, Imamura M, Endo N. Secondary osteosarcoma arising from osteochondroma following autologous stem cell transplantation with total-body irradiation for neuroblastoma: A case report. Oncol Lett 2015; 10:1026-1030. [PMID: 26622619 DOI: 10.3892/ol.2015.3257] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 05/08/2015] [Indexed: 11/06/2022] Open
Abstract
The present study reports the first case of malignant transformation to osteosarcoma arising from osteochondroma following childhood total-body irradiation (TBI). The association between TBI and later development of osteochondroma is well-known; however, malignant degeneration arising from radiation-induced osteochondroma is rare. The current study describes the case of a 17-year-old boy with osteosarcoma arising from osteochondroma of the left distal humerus, which developed following TBI. TBI was administered as part of a conditioning regimen received prior to autologous peripheral hematopoietic stem cell transplantation (HSCT) at the age of 6 years, following an initial diagnosis of neuroblastoma at the age of 5 years. The patient subsequently underwent preoperative chemotherapy followed by wide local excision and reconstruction with an extracorporeally irradiated autograft. Postoperative chemotherapy was administered, and the patient demonstrated no clinical or radiographic evidence of recurrence after 40 months of follow-up. To the best of our knowledge, this is only the second reported case of malignant degeneration of osteochondroma following childhood TBI, and the first reported case of transformation to osteosarcoma. The current case highlights the importance of close observation for secondary malignancies in this patient population.
Collapse
Affiliation(s)
- Hiroyuki Kawashima
- Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Akira Ogose
- Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Tetsuo Hotta
- Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Chihaya Imai
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Masaharu Imamura
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| | - Naoto Endo
- Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan
| |
Collapse
|
22
|
Morino S, Nishiguchi S, Fukutani N, Adachi D, Tashiro Y, Hotta T, Shirooka H, Nozaki Y, Hirata H, Yamaguchi M, Matsumoto D, Aoyama T. Association between pelvic asymmetry and lumbopelvic pain during pregnancy. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Matsuda K, Hotta T, Takifuji K, Yokoyama S, Oku Y, Watanabe T, Mitani Y, Ieda J, Mizumoto Y, Yamaue H. Randomized clinical trial of defaecatory function after anterior resection for rectal cancer with high versus low ligation of the inferior mesenteric artery. Br J Surg 2015; 102:501-8. [DOI: 10.1002/bjs.9739] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 10/10/2014] [Accepted: 11/10/2014] [Indexed: 12/11/2022]
Abstract
Abstract
Background
Defaecatory function is often poor after anterior resection. Denervation of the neorectum following high ligation of the inferior mesenteric artery (IMA) is a possible cause of impaired defaecatory function. The purpose of this randomized clinical trial was to clarify whether the level of ligation of the IMA in patients with rectal cancer affects defaecatory function.
Methods
Between 2008 and 2011, patients who underwent anterior resection for rectal cancer were randomized to receive either high or low ligation of the IMA. The primary endpoint was to demonstrate the superiority of low ligation in terms of defaecatory function.
Results
One hundred patients were enrolled in the study; 51 were randomized to high ligation of the IMA and 49 to low ligation. There were no differences between the groups in terms of clinical data, except tumour stage, which was more advanced in the high-ligation group (P = 0·046). Nor were there any differences in defaecatory function, self-assessment of defaecation, Faecal Incontinence Quality of Life scale or continence score between groups at 3 months and 1 year. The number of harvested lymph nodes was similar. The rate of symptomatic anastomotic leakage was 16 per cent in the high-ligation group and 10 per cent in the low-ligation group (P = 0·415).
Conclusion
The level of ligation of the IMA in patients with rectal cancer did not affect defaecatory function or the incidence of postoperative complications. Registration number: NCT00701012 (http://www.clinicaltrials.gov).
Collapse
Affiliation(s)
- K Matsuda
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - T Hotta
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - K Takifuji
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - S Yokoyama
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - Y Oku
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - T Watanabe
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - Y Mitani
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - J Ieda
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - Y Mizumoto
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| | - H Yamaue
- Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1, Kimiidera, Wakayama 641-8510, Japan
| |
Collapse
|
24
|
Adachi D, Fukutani N, Nishiguchi S, Hotta T, Morino S, Tashiro Y, Hirata H, Nozaki Y, Shirooka H, Yamaguchi M, Yamada M, Aoyama T. P218: Differences in chest wall mobility and respiratory function among age groups: a cross-sectional study of the healthy elderly. Eur Geriatr Med 2014. [DOI: 10.1016/s1878-7649(14)70392-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Ogose A, Hotta T, Kawashima H, Yamagiwa H, Endo N, Umezu H. Teaching NeuroImages: Recurrence of a sural intraneural ganglion cyst after sural nerve resection. Neurology 2014; 83:e95-6. [DOI: 10.1212/wnl.0000000000000714] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Sasaki T, Ogose A, Kawashima H, Hotta T, Hatano H, Ariizumi T, Umezu H, Ohashi R, Tohyama T, Tanabe N, Endo N. Real-time polymerase chain reaction analysis of MDM2 and CDK4 expression using total RNA from core-needle biopsies is useful for diagnosing adipocytic tumors. BMC Cancer 2014; 14:468. [PMID: 24965044 PMCID: PMC4075630 DOI: 10.1186/1471-2407-14-468] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2014] [Accepted: 06/19/2014] [Indexed: 12/31/2022] Open
Abstract
Background Diagnosing adipocytic tumors can be challenging because it is often difficult to morphologically distinguish between benign, intermediate and malignant adipocytic tumors, and other sarcomas that are histologically similar. Recently, a number of tumor-specific chromosome translocations and associated fusion genes have been identified in adipocytic tumors and atypical lipomatous tumors/well-differentiated liposarcomas (ALT/WDL), which have a supernumerary ring and/or giant chromosome marker with amplified sequences of the MDM2 and CDK4 genes. The purpose of this study was to investigate whether quantitative real-time polymerase chain reaction (PCR) could be used to amplify MDM2 and CDK4 from total RNA samples obtained from core-needle biopsy sections for the diagnosis of ALT/WDL. Methods A series of lipoma (n = 124) and ALT/WDL (n = 44) cases were analyzed for cytogenetic analysis and lipoma fusion genes, as well as for MDM2 and CDK4 expression by real-time PCR. Moreover, the expression of MDM2 and CDK4 in whole tissue sections was compared with that in core-needle biopsy sections of the same tumor in order to determine whether real-time PCR could be used to distinguish ALT/WDL from lipoma at the preoperative stage. Results In whole tissue sections, the medians for MDM2 and CDK4 expression in ALT/WDL were higher than those in the lipomas (P < 0.05). Moreover, karyotype subdivisions with rings and/or giant chromosomes had higher MDM2 and CDK4 expression levels compared to karyotypes with 12q13-15 rearrangements, other abnormal karyotypes, and normal karyotypes (P < 0.05). On the other hand, MDM2 and CDK4 expression levels in core-needle biopsy sections were similar to those in whole-tissue sections (MDM2: P = 0.6, CDK4: P = 0.8, Wilcoxon signed-rank test). Conclusion Quantitative real-time PCR of total RNA can be used to evaluate the MDM2 and CDK4 expression levels in core-needle biopsies and may be useful for distinguishing ALT/WDL from adipocytic tumors. Thus, total RNA from core-needle biopsy sections may have potential as a routine diagnostic tool for other tumors where gene overexpression is a feature of the tumor.
Collapse
Affiliation(s)
- Taro Sasaki
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, 757-1, Asahimachi-dori, Niigata City, Niigata 951-8510, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
|
28
|
Kasahara Y, Iwabuchi H, Takachi T, Hosokai R, Yoshida S, Imamura M, Watanabe A, Umezu H, Hotta T, Ogose A, Imai C. Alveolar rhabdomyosarcoma after treatment of osteosarcoma. Pediatr Int 2013; 55:527-30. [PMID: 23910806 DOI: 10.1111/ped.12070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2011] [Revised: 08/31/2012] [Accepted: 02/01/2013] [Indexed: 12/01/2022]
Abstract
Secondary rhabdomyosarcoma (RMS) after treatment of osteosarcoma (OS) is rare. Reported here is the case of a metachronous RMS in the nasal cavity, developing 12 years after successful treatment of non-metastatic OS. The patient was diagnosed as having OS of the femur at 2 years of age. Chemotherapy for OS included doxorubicin (cumulative dose, 488 mg/m(2) ). No radiotherapy was given. There was no family history suggestive of cancer predisposition syndrome. At 14 years of age, alveolar RMS was diagnosed on histopathology. PAX3-FKHR fusion transcripts were detected on reverse transcription-polymerase chain reaction. Germline TP53 mutation was not seen on standard DNA sequencing. The occurrence of secondary sarcomas, in the Children's Cancer Survivor study conducted in North America, has been associated with high cumulative doses of anthracyclines, which may also have played a role in the development of RMS in the present case. In the future, novel molecular technologies might uncover genetic cancer predisposition in patients with metachronous cancers.
Collapse
Affiliation(s)
- Yasushi Kasahara
- Division of Pediatrics, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Li GD, Kawashima H, Ogose A, Ariizumi T, Hotta T, Kuwano R, Urata Y, Fujiwara T, Endo N. Telomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells. Cancer Sci 2013; 104:1178-88. [PMID: 23718223 DOI: 10.1111/cas.12208] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 05/08/2013] [Accepted: 05/08/2013] [Indexed: 01/09/2023] Open
Abstract
This study investigated the pathway underlying the antitumor activity of telomelysin, a telomerase-dependent, replication-selective oncolytic adenovirus, in soft tissue sarcoma cells. Treatment with telomelysin alone resulted in simultaneous induction of apoptosis and autophagy, whereas cotreatment with telomelysin and 3-methyladenine significantly reduced cell viability and increased apoptosis and the cellular ATP level compared to treatment with telomelysin alone, indicating that telomelysin-mediated autophagy is a death-protective but not death-promoting process. Cotreatment with Z-Val-Ala-Asp-CH2F significantly increased cellular ATP depletion compared to telomelysin-alone treatment while inhibiting telomelysin-induced apoptosis and having no significant effect on cell viability, indicating that it promotes transition from apoptotic to necrotic cell death.
Collapse
Affiliation(s)
- Gui-Dong Li
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Ariizumi T, Ogose A, Kondo N, Kawashima H, Hotta T, Kudo N, Hoshino M, Inoue H, Irie H, Endo N. The Role of Microstructure of Highly Purified Beta-Tricalcium Phosphate for Osteoinduction in Canine Dorsal Muscles. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/jbnb.2013.42023] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
31
|
Li GD, Ogose A, Hotta T, Kawashima H, Ariizumi T, Xu Y, Endo N. Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report. Oncol Lett 2012; 2:1239-1242. [PMID: 22848294 DOI: 10.3892/ol.2011.369] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2011] [Accepted: 07/19/2011] [Indexed: 11/06/2022] Open
Abstract
Polyostotic fibrous dysplasia (PFD) is a high- turnover bone disease that frequently entails chronic bone pain, pathological fractures and severe deformities. Recently, bisphosphonates have shown effective antiresorptive properties in the treatment of children or adults with PFD. We report on a 79-year-old female with PFD, who had severe lower limb deformity and chronic bone pain in multiple sites of her extremities for more than 55 years. The patient experienced significant decrease in bone pain and bone turnover markers following long-term (8.5 years) treatment with a low-dose oral alendronate treatment (5 mg/day). To the best of our knowledge, this is the first report of a long-term follow-up of a postmenopausal elderly patient with long-standing symptomatic PFD following continuous low-dose oral alendronate therapy. This case report indicates that long-term daily administration of low-dose alendronate alone is a potential treatment option for elderly patients with PFD, particularly those with long-standing bone pain.
Collapse
Affiliation(s)
- Gui-Dong Li
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan
| | | | | | | | | | | | | |
Collapse
|
32
|
Hwang SH, Hicks K, Ahn JK, Nakano T, Ahn DS, Chang WC, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Gohn W, Hotta T, Imai K, Ishikawa T, Joo K, Kato Y, Kohri H, Kon Y, Lee HS, Maeda Y, Miyabe M, Mibe T, Morino Y, Muramatsu N, Nakatsugawa Y, Niiyama M, Noumi H, Oh Y, Ohashi Y, Ohta T, Oka M, Parker J, Rangacharyulu C, Ryu SY, Sawada T, Sugaya Y, Sumihama M, Tsunemi T, Uchida M, Ungaro M, Yosoi M. Spin-density matrix elements for γp→K*0Σ+ at Eγ=1.85-3.0 GeV with evidence for the κ(800) meson exchange. Phys Rev Lett 2012; 108:092001. [PMID: 22463625 DOI: 10.1103/physrevlett.108.092001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2011] [Indexed: 05/31/2023]
Abstract
The exclusive reaction γp→K(+)π(-)Σ(+) was measured for the first time using linearly polarized photons at beam energies from 1.85 to 2.96 GeV. Angular distributions in the rest frame of the K(+)π(-) system were fitted to extract spin-density matrix elements of the K(*0) decay. The measured parity spin asymmetry shows that natural-parity exchange is dominant in this reaction. This result clearly indicates the need for t-channel exchange of the κ(800) scalar meson.
Collapse
Affiliation(s)
- S H Hwang
- Department of Physics, Pusan National University, Busan 609-735, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Katsumata N, Fujiwara Y, Sugiyama T, Goto I, Ohmatsu H, Okamoto R, Ohashi Y, Saijo N, Hotta T, Ariyoshi Y. 3066 POSTER Erythropoiesis-stimulating Agents for the Treatment of Chemotherapy-induced Anemia and Mortality: a Meta-analysis of Individual Patient Data From Japanese Randomized Trials. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71139-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
35
|
Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, Hirose T, Endo N. Establishment and characterization of a novel dedifferentiated liposarcoma cell line, NDDLS-1. Pathol Int 2011; 61:461-8. [PMID: 21790860 DOI: 10.1111/j.1440-1827.2011.02683.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
We established a dedifferentiated liposarcoma cell line (NDDLS-1) that produces interleukin-6 (IL-6) and granulocyte-colony stimulating factor (G-CSF). The parental tumor showed high leukemoid reactions. The NDDLS-1 cell line was established from a pleural effusion associated with a lung metastasis. Pleomorphic tumor cells arranged in a haphazard growth pattern were seen in xenograft tumors. Numerous inflammatory cells including neutrophils or eosinophils were present throughout the tumor cells. This finding resembled the dedifferentiated area of the parental tumor. The mice bearing NDDLS-1 showed marked leukocytosis. In addition, the NDDLS-1 cells expressed IL-6 and G-CSF at both the mRNA and protein levels, while the NDDLS-1 cells produced near normal levels of tumor necrosis factor alpha (TNF-α). In the cytogenetic analysis, both the parental tumor and the NDDLS-1 cells showed a ring or giant marker chromosomes. The NDDLS-1 cell line demonstrated the amplification and expression of both MDM2 and CDK4 by fluorescence in situ hybridization and immunohistochemical analysis. The NDDLS-1 cell line is consistent with the parental dedifferentiated liposarcoma, and it should therefore be useful for further investigations of human dedifferentiated liposarcomas.
Collapse
Affiliation(s)
- Takashi Ariizumi
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Ohmachi K, Tobinai K, Kobayashi Y, Itoh K, Nakata M, Shibata T, Morishima Y, Ogura M, Suzuki T, Ueda R, Aikawa K, Nakamura S, Fukuda H, Shimoyama M, Hotta T. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011; 22:1382-1391. [DOI: 10.1093/annonc/mdq619] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezu H, Endo N. High-level expression of podoplanin in benign and malignant soft tissue tumors: immunohistochemical and quantitative real-time RT-PCR analysis. Oncol Rep 2011; 25:599-607. [PMID: 21234520 DOI: 10.3892/or.2011.1141] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Accepted: 11/30/2010] [Indexed: 11/06/2022] Open
Abstract
Podoplanin is a 38 kDa mucin-type transmembrane glycoprotein that was first identified in rat glomerular epithelial cells (podocytes). It is expressed in normal lymphatic endothelium, but is absent from vascular endothelial cells. D2-40 is a commercially available mouse monoclonal antibody which binds to an epitope on human podoplanin. D2-40 immunoreactivity is therefore highly sensitive and specific for lymphatic endothelium. Recent investigations have shown widespread applications of immunohistochemical staining with D2-40 in evaluating podoplanin expression as an immunohistochemical marker for diagnosis and prognosis in various tumors. To determine whether the podoplanin (D2-40) antibody may be useful for the diagnosis of soft tissue tumors, 125 cases, including 4 kinds of benign tumors, 15 kinds of malignant tumors and 3 kinds of tumor-like lesions were immunostained using the D2-40 antibody. Total RNA was extracted from frozen tumor tissue obtained from 41 corresponding soft tissue tumor patients and 12 kinds of soft tissue tumor cell lines. Quantitative real-time PCR reactions were performed. Immunohistochemical and quantitative real-time RT-PCR analyses demonstrated the expression of the podoplanin protein and mRNA in the majority of benign and malignant soft tissue tumors and tumor-like lesions examined, with the exception of alveolar soft part sarcoma, embryonal and alveolar rhabdomyosarcoma, extraskeletal Ewing's sarcoma/peripheral primitive neuro-ectodermal tumor and lipoma, which were completely negative for podoplanin. Since it is widely and highly expressed in nearly all kinds of soft tissue tumors, especially in spindle cell sarcoma, myxoid type soft tissue tumors and soft tissue tumors of the nervous system, podoplanin is considered to have little value in the differential diagnosis of soft tissue tumors.
Collapse
Affiliation(s)
- Yongjun Xu
- Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata University Medical and Dental Hospital, 757-1, Asahimachi-dori, Niigata City, Niigata Prefecture 951-8510, Japan
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Li G, Kawashima H, Ji L, Ogose A, Ariizumi T, Umezu H, Xu Y, Hotta T, Endo N. Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas. Anticancer Res 2011; 31:11-21. [PMID: 21273575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
BACKGROUND FUS1 is a tumor suppressor gene located on human chromosome 3p21.3. Frequent loss of FUS1 protein expression is associated with lung cancer development. This study examined FUS1 expression and its possible tumor-suppressive role in bone and soft tissue sarcomas. MATERIALS AND METHODS The expressions of FUS1 mRNA and FUS1 protein were assessed in sarcoma cell lines, sarcoma tissues, benign bone and soft-tissue tumor (BST) tissues, and healthy tissues. Exogenous FUS1 gene transfection was performed on sarcoma cell lines. RESULTS FUS1 mRNA expression was detected in all sarcoma cell lines, all benign BSTs and healthy tissues, and almost all sarcoma tissues. In contrast, FUS1 protein expression was frequently lost in sarcoma cells and sarcoma tissues. The exogenous FUS1 gene delivery induced strong FUS1 protein expression, inhibition of cell viability and apoptosis in sarcoma cells. CONCLUSION FUS1 may act as a tumor suppressor in bone and soft-tissue sarcomas.
Collapse
Affiliation(s)
- Guidong Li
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hatano H, Morita T, Kawashima H, Ogose A, Hotta T. Symptomatic elastofibroma in young baseball pitchers: report of three cases. J Shoulder Elbow Surg 2010; 19:e7-10. [PMID: 20850999 DOI: 10.1016/j.jse.2010.05.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2010] [Revised: 05/24/2010] [Accepted: 05/25/2010] [Indexed: 02/01/2023]
Affiliation(s)
- Hiroshi Hatano
- Department of Orthopedic Surgery, Niigata Cancer Hospital, Niigata, Japan.
| | | | | | | | | |
Collapse
|
40
|
Tobinai K, Ogura M, Hatake K, Kobayashi Y, Mori M, Uchida T, Suzuki T, Terui Y, Yokoyama M, Hotta T. Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Terui Y, Ogura M, Tobinai K, Hatake K, Suzuki T, Maruyama D, Miyazato A, Katsura K, Hotta T. Phase I study of ofatumumab (OFA) in Japanese patients (JPN pts) with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Kohri H, Ahn DS, Ahn JK, Akimune H, Asano Y, Chang WC, Daté S, Ejiri H, Fukui S, Fujimura H, Fujiwara M, Hasegawa S, Hicks K, Hosaka A, Hotta T, Imai K, Ishikawa T, Iwata T, Kawai H, Kim ZY, Kino K, Kumagai N, Makino S, Matsuda T, Matsumura T, Matsuoka N, Mibe T, Miyabe M, Miyachi Y, Morita M, Muramatsu N, Nakano T, Nam SI, Niiyama M, Nomachi M, Ohashi Y, Ohkuma H, Ooba T, Oshuev DS, Rangacharyulu C, Sakaguchi A, Sasaki T, Shagin PM, Shiino Y, Shimizu A, Shimizu H, Sugaya Y, Sumihama M, Titov AI, Toi Y, Toyokawa H, Wakai A, Wang CW, Wang SC, Yonehara K, Yorita T, Yoshimura M, Yosoi M, Zegers RGT. Near-threshold Lambda(1520) production by the gamma(p)-->K{+}Lambda(1520) reaction at forward K+ angles. Phys Rev Lett 2010; 104:172001. [PMID: 20482102 DOI: 10.1103/physrevlett.104.172001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2009] [Indexed: 05/29/2023]
Abstract
Differential cross sections and photon-beam asymmetries for the gamma(p)-->K{+}Lambda(1520) reaction have been measured with linearly polarized photon beams at energies from the threshold to 2.4 GeV at 0.6<cos(theta){c.m.}{K}<1. A new bump structure was found at W approximately 2.11 GeV in the cross sections. The bump is not well reproduced by theoretical calculations introducing a nucleon resonance with J<or=3/2. This result suggests that the bump might be produced by a nucleon resonance possibly with J>or=5/2 or by a new reaction process, for example, an interference effect with the phi photoproduction having a similar bump structure in the cross sections.
Collapse
Affiliation(s)
- H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, Umezu H, Sugai M, Endo N. Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol Int 2010; 60:193-202. [DOI: 10.1111/j.1440-1827.2009.02510.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
44
|
Ogose A, Hotta T, Shibata M, Kawashima H, Endo N. Combined use of free vascularised fibula graft and extracorporeally irradiated osteochondral graft for osteosarcoma of the proximal ulna. Oncol Lett 2010; 1:133-135. [PMID: 22966270 DOI: 10.3892/ol_00000024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2009] [Accepted: 08/06/2009] [Indexed: 11/06/2022] Open
Abstract
The elbow is an uncommon site for malignant bone tumors. Surgical options for the reconstruction of the elbow joint are limited and technically challenging. In this study, we describe a patient with osteosarcoma of the proximal ulna treated by wide resection and reconstruction with a combined use of free vascularised fibula graft and extracorporeally irradiated osteochondral graft. Ten years after the surgery, the patient is alive, without disease and is able to play golf with no lateral instability or pain of the elbow joint. A vascularised fibula, combined with extracorporeally irradiated osteochondral graft with ligamentous repair is one of the options for the treatment of malignant bone tumor of the proximal ulna.
Collapse
Affiliation(s)
- Akira Ogose
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
| | | | | | | | | |
Collapse
|
45
|
Muramatsu N, Chen JY, Chang WC, Ahn DS, Ahn JK, Akimune H, Asano Y, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Hasegawa S, Hicks K, Horie K, Hotta T, Imai K, Ishikawa T, Iwata T, Kato Y, Kawai H, Kino K, Kohri H, Kumagai N, Makino S, Matsuda T, Matsumura T, Matsuoka N, Mibe T, Miyabe M, Miyachi M, Nakano T, Niiyama M, Nomachi M, Ohashi Y, Ohkuma H, Ooba T, Oshuev DS, Rangacharyulu C, Sakaguchi A, Shagin PM, Shiino Y, Shimizu H, Sugaya Y, Sumihama M, Toi Y, Toyokawa H, Wakai A, Wang CW, Wang SC, Yonehara K, Yorita T, Yoshimura M, Yosoi M, Zegers RGT. Near-threshold photoproduction of Lambda(1520) from protons and deuterons. Phys Rev Lett 2009; 103:012001. [PMID: 19659135 DOI: 10.1103/physrevlett.103.012001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2009] [Indexed: 05/28/2023]
Abstract
Photoproduction of Lambda(1520) with liquid hydrogen and deuterium targets was examined at photon energies below 2.4 GeV in the SPring-8 LEPS experiment. For the first time, the differential cross sections were measured at low energies and with a deuterium target. A large asymmetry of the production cross sections from protons and neutrons was observed at backward K+/0 angles. This suggests the importance of the contact term, which coexists with t-channel K exchange under gauge invariance. This interpretation was compatible with the differential cross sections, decay asymmetry, and photon beam asymmetry measured in the production from protons at forward K+ angles.
Collapse
Affiliation(s)
- N Muramatsu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Hoshino M, Ogose A, Kawashima H, Izumi T, Hotta T, Hatano H, Morita T, Otsuka H, Umezu H, Yanoma S, Tsukuda M, Endo N. Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma. ACTA ACUST UNITED AC 2009; 190:75-80. [PMID: 19380023 DOI: 10.1016/j.cancergencyto.2008.11.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2008] [Revised: 11/30/2008] [Accepted: 12/18/2008] [Indexed: 10/20/2022]
Abstract
Alveolar soft part sarcoma (ASPS) is a distinct, rare soft tissue tumor with an unknown histogenesis and a tendency for late widespread metastases to lung, bone, and brain. It is now clear that they are caused by a specific unbalanced translocation, der(17)t(X;17)(p11;q25), which results in the formation of an ASPSCR1-TFE3 (alias ASPL-TFE3) fusion gene. The rearrangement results in the expression of chimeric transcripts, which can be identified by means of reverse transcriptase-polymerase chain reaction (RT-PCR). We investigated the histogenesis of ASPS and attempted to detect circulating ASPS tumor cells in peripheral blood. The immunohistochemical and genetic details of four cases and one cell line of ASPS were examined. An immunohistochemical analysis and RT-PCR did not detect myogenic differentiation gene MYOD1. The sensitivity of nested RT-PCR for detection of circulating ASPS cells was assessed by demonstrating that the tumor cell-associated gene translocation could be detected in 50 tumor cells/2 mL of blood. Clinically, it was detectable in a peripheral blood sample (2 mL) of ASPS patient with distant metastases. The findings suggest that ASPS is not of skeletal muscle origin. ASPS tumor cells in the peripheral blood could be monitored by RT-PCR.
Collapse
Affiliation(s)
- Makiko Hoshino
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1-751, Niigata 951-8510, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Li G, Ogose A, Kawashima H, Umezu H, Hotta T, Tohyama T, Ariizumi T, Endo N. Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma. ACTA ACUST UNITED AC 2009; 192:1-9. [PMID: 19480930 DOI: 10.1016/j.cancergencyto.2009.02.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2008] [Accepted: 02/12/2009] [Indexed: 10/20/2022]
Abstract
Pleomorphic rhabdomyosarcoma (PRMS) is a rare variant of rhabdomyosarcoma that occurs mostly in adults. A few cytogenetic studies of PRMS have been reported, but no consistent specific chromosome aberrations were detected. We herein report a cytogenetic study of three cases of pleomorphic rhabdomyosarcoma using a conventional G-banded karyotyping analysis. The three cases appeared to exhibit an extremely complex karyotype with numeric and structural rearrangements. Although the three cases displayed several common aberrations, including -2, -4, -9, -13, -14, -15, -19, -21, add(X)(p11), add(1)(q11), add(7)(p11), and add(13)(p11), no recurrent characteristic chromosomal aberrations could be detected. In addition, among these cases and seven other cases of previously reported PRMS, the most frequent chromosomal alterations were -2, -13, -14, -15, -16, and -19. No obviously consistent structural alterations can be found in these 10 PRMS cases, however, thereby suggesting that it is difficult to confirm whether these complex karyotypes correlated with the diagnosis or clinical outcome in PRMS. In this study, we detected MyoD1 and myogenin gene transcripts at the mRNA level in four cases of PRMS together with other soft-tissue sarcomas, including seven cases of malignant fibrous hitiocytoma, five cases of liposacroma, and three cases of leiomyosacroma using a real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. High-level expressions of MyoD1 and myogenin gene transcripts were determined in all cases of PRMS. In contrast, the other non-PRMS sarcomas showed either no expression or extremely weak expressions for both genes. Our findings suggest that the detections of MyoD1 and myogenin transcripts using real-time quantitative RT-PCR, combined with immunohistochemical stains, are extremely sensitive and useful for the diagnosis of PRMS.
Collapse
Affiliation(s)
- Guidong Li
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University Hospital, Niigata, Japan
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Kudo N, Ogose A, Ariizumi T, Kawashima H, Hotta T, Hatano H, Morita T, Nagata M, Siki Y, Kawai A, Hotta Y, Hoshino M, Endo N. Expression of bone morphogenetic proteins in giant cell tumor of bone. Anticancer Res 2009; 29:2219-2225. [PMID: 19528484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND A giant cell tumor (GCT) of bone is a locally aggressive tumor with a propensity for local recurrence. A characteristic pattern of peripheral bone formation has been described in GCT recurrence in soft tissue, and in some pulmonary metastases from benign GCT. Although the bone formation in GCT in supposedly due to bone morphogenetic proteins (BMPs), the expression pattern of BMPs in GCT has not been well investigated. MATERIALS AND METHODS The expression of BMPs in GCT tissues, cultured stromal cells from GCT, and osteoclast-like giant cells harvested by laser microdissection (LM), as well as from control osteosarcoma (NOS-1) cells was analyzed using reverse transcriptional-semiquantitative PCR. RESULTS BMP 2, 3, 4, 5 and 6 were expressed in the GCT tissue. The cultured GCT cells expressed BMP 2, 4, 5 and 6. The osteoclast-like giant cells expressed BMP 2, 3, 5 and 6 and BMP 5 was expressed at the highest level. CONCLUSION Both stromal cells and osteoclast-like cells in GCT expressed several kinds of BMPs.
Collapse
Affiliation(s)
- Naoko Kudo
- Division of Orthopedic Surgery, Department of Regenerative Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata City, Niigata 951-8510, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Yamaguchi M, Tobinai K, Oguchi M, Isobe Y, Ishizawa K, Maseki N, Wasada I, Ishizuka N, Hotta T, Oshimi K. Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8549] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8549 Background: Nasal NK/T-cell lymphoma is rare and its standard therapy has not been established. Tumor cells express P-glycoprotein concerning multi-drug resistance (MDR). Anthracycline-containing chemotherapy is not effective and %2-yr overall survival (OS) of radiotherapy (RT) alone is only 45%. Methods: To explore a more effective treatment for localized nasal NK/T-cell lymphoma, we conducted a phase I/II study of concurrent chemoradiotherapy consisted of 50 Gy of RT and 3 courses of DeVIC [carboplatin (CBDCA), etoposide (ETP), ifosfamide (IFM), dexamethasone (DMS)]. Patients (Pts) with newly-diagnosed, localized (IE & contiguous IIE with cervical node involvement) diseases, 20–69 years of age and PS 0–2 were eligible. The 3-D conformal RT planning was required to cover adequately target volumes (2 cm margin to gross tumor, entire nasal cavities and nasopharynx) and to minimize doses to organs at risk. Primary endpoint of the phase II portion was 2-yr OS and the enrollment of 24 pts to the phase II portion was planned. Based on the results of the phase I portion (ASH 2005, #2685), 2/3-dose of DeVIC (CBDCA 200mg/m2 d1 IV, ETP 67mg/m2 d1–3 IV, IFM 1.0g/m2 d1–3 IV, DMS 40mg/body d1–3 IV; every 3 wks) was applied for the phase II portion. RT quality assurance review confirmed no protocol violation (ASTRO 2008, #2682). Results: From Sep 2003 to Dec 2006, 33 pts were enrolled in the phase I/II study. 27 pts evaluated in the phase II portion showed the following features: age 21–68 yrs (median 56), M:F=17:10, stage IE 18, stage IIE 9, B symptom (+) 10, elevated serum LDH 5, PS2 2. With a median follow-up of 32 months (range, 24–62), %2-yr OS was 78% (95% CI, 57–89). Of 26 pts evaluable for response, 20 achieved CR, 1 PR, 2SD, and 3PD. %CR and %ORR were 77% (95% CI, 56–91) and 81%, respectively. The most common grade 3 non-hematologic toxicities were mucositis due to RT (30%) and infection (30%). Grade 4 hyponatremia and dermatitis due to RT were observed in each 1 pt. No treatment-related death was observed. Conclusions: Concurrent chemoradiotherapy using MDR-non-related agents and ETP is a safe and effective treatment for localized nasal NK/T-cell lymphoma, providing the basis for subsequent studies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Yamaguchi
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - K. Tobinai
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - M. Oguchi
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - Y. Isobe
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - K. Ishizawa
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - N. Maseki
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - I. Wasada
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - N. Ishizuka
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - T. Hotta
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| | - K. Oshimi
- Mie University, Tsu, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital, Tokyo, Japan; Juntendo University, Tokyo, Japan; Tohoku University, Sendai, Japan; Saitama Cancer Center, Saitama, Japan; Tokai University, Isehara, Japan; International Medical Center of Japan, Tokyo, Japan; NHO Nagoya Medical Center, Nagoya, Japan
| |
Collapse
|
50
|
Nagai H, Kusumoto S, Sawada K, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Omachi K, Ogura M, Hotta T. Phase II study of cladribine with rituximab (R-2-CdA) therapy in patients with relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19501 Background: Although cladribine has been reported to be one of active purine analogs against indolent B-cell non-Hodgkin's lymphoma (B-NHL), there are few reports of combination usage of cladribine and rituximab. We conducted a multicenter phase II study to investigate efficacy and toxicity of cladribine with rituximab (R-2-CdA) therapy for relapsed indolent B-NHL. Methods: Eligibility criteria were as follows: relapsed pts with indolent B-NHL from systemic chemotherapy, ages less than 75 years; PS 0–2 by ECOG's scale. Patients received 0.09mg/kg of cladribine intravenously (2 hrs infusion) on days 1 to 5 and 375mg/m2 of rituximab intravenously on days 1 and 15, every 4 weeks, for a total of 4 cycles. Primary endpoint was overall response rate (ORR). Secondary endpoints were % complete response (%CR), 2 years progression free survival (2-y PFS), and 2 years overall survival (2-y OS). Results: A total of 20 out of 45 planned patients were enrolled and received R-2-CdA therapy from Apr 2005 to Jul 2007. Their median age was 58.5 (42–72), and the median number of prior regimens was 2 (1–3). Histologies included 16 follicular lymphomas, 2 MALT lymphomas, 1 nodal marginal B cell lymphoma, and 1 lymphoplasmacytic lymphoma. Fifteen pts (75%) were previously treated with rituximab. The ORR was 90% with 70% of % CR. Median PFS was 20.1 months (5.6–32.9 months) at a median follow-up time of 27 months. 2-y PFS and 2-y OS were 63.2% (95%CI, 28.1–67.8%), and 89.5% (95%CI, 69.8–97.2%), respectively. Severe neutropenia and thrombocytopenia of grade 3 or 4 were observed in 15% and 10% respectively. Conclusions: R-2CdA therapy was demonstrated to have high activity with durable PFS and acceptable toxicity in relapsed indolent B-NHL, even if patients were previously treated with rituximab. Although a large-scaled further trial remains to be needed, R-2-CdA therapy could be a good option of salvage therapy in relapsed indolent B-NHL. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Nagai
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - S. Kusumoto
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - K. Sawada
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - M. Yamaguchi
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - N. Takayama
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - T. Kinoshita
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - T. Motoji
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - K. Omachi
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - M. Ogura
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| | - T. Hotta
- National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Nagoya City University Graduate School of Medicine, Nagoya, Japan; Akita University School of Medicine, Akita, Japan; Mie University Graduate School of Medicine, Tsu, Japan; Kyorin University Graduate School of Medicine, Mitaka, Japan; Nagoya University Graduate School of Medicine, Nagoya, Japan; Tokyo Women's Medical University, Tokyo, Japan; Tokai University School of Medicine, Isewara, Japan; Nagoya Daini Red Cross Hospital, Naogoya,
| |
Collapse
|